Todd Brady
Chief Executive Officer bei ALDEYRA THERAPEUTICS, INC.
Vermögen: 5 Mio $ am 31.03.2024
Profil
Todd C.
Brady is the founder of Phenome Sciences, Inc. He currently holds the position of President, Chief Executive Officer & Director at Aldeyra Therapeutics, Inc. since 2012.
He is also the President, CEO, Secretary & Director at Helio Vision, Inc. Additionally, he serves as an Independent Director at Evoke Pharma, Inc. since 2007, and as a Director at NovaDigm Therapeutics, Inc. since 2007.
He is a Member of Southeast BIO.
In his former positions, Dr. Brady served as the Medical Director & Head of Business Development at ADERIS Pharmaceuticals, Inc. He was also a Director at Cantex Pharmaceuticals, Inc., Sebacia, Inc., Asmacure Ltée, CardioPolymers, Inc., and F-Star Therapeutics, Inc. (United States).
He served as an Independent Director at Outlook Therapeutics, Inc. from 2014 to 2017, and he will serve as an Independent Director at F-star Therapeutics, Inc. from 2020 to 2023.
He was a Principal at Domain Associates LLC and the Executive VP of Strategic Development & Planning at Antisoma, Inc. He also worked as a Senior Associate at CB Health Ventures.
Dr. Brady completed his undergraduate degree at Dartmouth College in 1993.
He obtained his doctorate degree from Duke University School of Medicine in 1999.
He also attended Duke University Graduate School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 12.03.2024 | 1 471 298 ( 2,50% ) | 5 Mio $ | 31.03.2024 | |
EVOKE PHARMA, INC.
0,00% | 10.05.2023 | 333 ( 0,00% ) | 203 $ | 31.03.2024 |
Aktive Positionen von Todd Brady
| Unternehmen | Position | Beginn |
|---|---|---|
| EVOKE PHARMA, INC. | Director/Board Member | 01.06.2007 |
| ALDEYRA THERAPEUTICS, INC. | Chief Executive Officer | 01.01.2012 |
| Southeast BIO | Corporate Officer/Principal | - |
NovaDigm Therapeutics, Inc.
 NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | Director/Board Member | 01.12.2007 |
Helio Vision, Inc.
 Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | Chief Executive Officer | - |
Ehemalige bekannte Positionen von Todd Brady
| Unternehmen | Position | Ende |
|---|---|---|
| F-STAR THERAPEUTICS, INC. | Director/Board Member | 08.03.2023 |
| OUTLOOK THERAPEUTICS, INC. | Director/Board Member | 31.10.2017 |
| Phenome Sciences, Inc. | Chief Executive Officer | - |
ADERIS Pharmaceuticals, Inc.
 ADERIS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ADERIS Pharmaceuticals, Inc. develops and commercializes drugs and pharmaceuticals. It engages in small molecule drug development to treat central nervous system, cardiovascular, and inflammatory disorders. The company was founded by Donald McAfee, Noel Cusack, Gevork I. Minaskanian, and Peter Savasand in 1994 and is headquartered in Hopkinton, MA. | Chief Tech/Sci/R&D Officer | - |
| ░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Todd Brady
| Dartmouth College | Undergraduate Degree |
| Duke University School of Medicine | Doctorate Degree |
| Duke University Graduate School | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| ALDEYRA THERAPEUTICS, INC. | Health Technology |
| EVOKE PHARMA, INC. | Health Technology |
| OUTLOOK THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 14 |
|---|---|
ADERIS Pharmaceuticals, Inc.
ADERIS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ADERIS Pharmaceuticals, Inc. develops and commercializes drugs and pharmaceuticals. It engages in small molecule drug development to treat central nervous system, cardiovascular, and inflammatory disorders. The company was founded by Donald McAfee, Noel Cusack, Gevork I. Minaskanian, and Peter Savasand in 1994 and is headquartered in Hopkinton, MA. | Health Technology |
Cantex Pharmaceuticals, Inc.
 Cantex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cantex Pharmaceuticals, Inc. develops heparin to ameliorate cardiac ischemia-reperfusion injuries. It also develops medications to enhance the safety and effectiveness of existing cancer treatments. The firm provides Disulfiram + copper Chelate that includes non-overlapping cancer stem cell killing mechanisms of actions. The company was founded in 2013 by Thomas P. Kennedy, Neil William Flanzraich and Stephen G. Marcus and is headquartered in Weston, FL. | Health Technology |
Sebacia, Inc.
 Sebacia, Inc. BiotechnologyHealth Technology Sebacia, Inc. develops novel technology to treat acne. It also engages in the development of products for the dermatology market. The company was founded by Anthony V. Lando, Charles E. Larsen and Thomas D. Weldon in 2010 and is headquartered in Duluth, GA. | Health Technology |
Domain Associates LLC
 Domain Associates LLC Investment ManagersFinance Domain Associates LLC (Domain Associates) is a venture capital firm founded in 1985. The firm is headquartered in Princeton, New Jersey. | Finance |
Antisoma, Inc.
 Antisoma, Inc. Pharmaceuticals: MajorHealth Technology Antisoma, Inc. develops drugs and pharmaceuticals. The firm's products include Xanafide, Symadex, and Clomet. Its products are used in clinical and preclinical development for multiple cancer indications. The company was founded in 2001 and is headquartered Cambridge, MA. | Health Technology |
CB Health Ventures
 CB Health Ventures Investment ManagersFinance CB Health Ventures venture capital firm located in Boston | Finance |
Asmacure Ltée
 Asmacure Ltée Pharmaceuticals: MajorHealth Technology Asmacure Ltée develops novel, proprietary compounds that target cholinergic receptors for the treatment of inflammation, notably pulmonary airway diseases. The company was founded by Yvon Cormier and Evelyne Israel-Assayag in 2002 and is headquartered in Quebec, Canada. | Health Technology |
CardioPolymers, Inc.
 CardioPolymers, Inc. Pharmaceuticals: MajorHealth Technology CardioPolymers, Inc. provides novel biocompatible polymer implant therapies to treat cronic heart failures. The company was founded in 2003 and is headquartered in Laguna Hills, CA. | Health Technology |
| Southeast BIO | |
NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | Health Technology |
F-Star Therapeutics, Inc. (United States)
 F-Star Therapeutics, Inc. (United States) Pharmaceuticals: MajorHealth Technology F-Star Therapeutics, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA. | Health Technology |
| Phenome Sciences, Inc. | |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | Health Technology |
F-star Therapeutics, Inc.
 F-star Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
